Dr. Reddy's Laboratories (RDY) Expected to Announce Quarterly Earnings on Friday

Key Points

• Dr. Reddy’s Laboratories is expected to report Q2 fiscal 2026/27 results before market open on October 23, 2026. Analysts forecast earnings of $0.0951 per share and revenue of $891.54 million.
• The company’s previous quarter fell short of expectations, with EPS of $0.06 versus the $0.09 consensus, while revenue reached $850.26 million, nearly matching estimates.
• Analyst sentiment remains mixed: Citigroup and BNP Paribas Exane upgraded the stock, but the overall consensus rating is “Hold,” with a consensus target price of $732.40.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) will likely be announcing its Q2 26/27 results before the market opens on Friday, October 23rd. Analysts expect the company to announce earnings of $0.0951 per share and revenue of $891.54 million for the quarter. Interested persons may review the information on the company's upcoming Q2 26/27 earnings summary page for the latest details on the call scheduled for Friday, October 23, 2026 at 10:00 AM ET.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last announced its quarterly earnings data on Thursday, July 23rd. The company reported $0.06 earnings per share for the quarter, missing analysts' consensus estimates of $0.09 by ($0.03). The firm had revenue of $850.26 million during the quarter, compared to analyst estimates of $850.56 million. Dr. Reddy's Laboratories had a net margin of 10.15% and a return on equity of 9.49%. On average, analysts expect Dr. Reddy's Laboratories to post $0.45 EPS for the current fiscal year and $0.57 EPS for the next fiscal year.

Dr. Reddy's Laboratories Stock Performance

NYSE RDY opened at $12.91 on Friday. The stock has a 50-day simple moving average of $12.25 and a two-hundred day simple moving average of $12.92. The firm has a market capitalization of $10.78 billion, a P/E ratio of 29.35, a PEG ratio of 2.66 and a beta of 0.29. Dr. Reddy's Laboratories has a fifty-two week low of $11.36 and a fifty-two week high of $15.67. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.39 and a current ratio of 1.90.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on RDY. Citigroup raised shares of Dr. Reddy's Laboratories from a "sell" rating to a "buy" rating and lifted their target price for the company from $1,040.00 to $1,450.00 in a report on Tuesday, September 29th. Weiss Ratings downgraded shares of Dr. Reddy's Laboratories from a "hold (c)" rating to a "hold (c-)" rating in a report on Thursday, July 23rd. BNP Paribas Exane raised shares of Dr. Reddy's Laboratories to an "outperform" rating and set a $14.80 price target on the stock in a report on Monday. Finally, Wall Street Zen upgraded shares of Dr. Reddy's Laboratories from a "sell" rating to a "hold" rating in a research report on Saturday, August 29th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Dr. Reddy's Laboratories currently has a consensus rating of "Hold" and a consensus target price of $732.40.

Dr. Reddy's Laboratories Company Profile

Dr. Reddy's Laboratories Limited is a multinational pharmaceutical company headquartered in Hyderabad, India. Founded in 1984 by Dr. Kallam Anji Reddy, the company develops, manufactures and markets medicines intended to make healthcare more accessible.

Its business includes generic pharmaceuticals, branded generics, over-the-counter products, active pharmaceutical ingredients and biosimilars. Dr. Reddy's portfolio spans therapeutic areas such as gastrointestinal, cardiovascular, diabetes, oncology, pain management, dermatology and central nervous system treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.